Jürgen Kuball
A5056738351- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Acute Myeloid Leukemia Research
- Immunotherapy and Immune Responses
- Acute Lymphoblastic Leukemia research
- Cytomegalovirus and herpesvirus research
- Virus-based gene therapy research
- Renal Transplantation Outcomes and Treatments
- Chronic Myeloid Leukemia Treatments
- Mesenchymal stem cell research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- CRISPR and Genetic Engineering
- Polyomavirus and related diseases
- HIV Research and Treatment
- Biomedical Ethics and Regulation
- vaccines and immunoinformatics approaches
- Cancer Immunotherapy and Biomarkers
- Neutropenia and Cancer Infections
- HIV/AIDS drug development and treatment
- Cancer Research and Treatments
Utrecht University
2015-2025
University Medical Center Utrecht
2016-2025
Center for Translational Molecular Medicine
2018-2025
Heidelberg University
2017-2024
University Hospital Heidelberg
2017-2024
Princess Máxima Center
2024
European Society for Blood and Marrow Transplantation
2023
University Medical Center
2012-2018
Fred Hutch Cancer Center
2006-2013
University of Washington
2006-2013
Half the patients with acute myeloid leukemia (AML) who achieve complete remission (CR), ultimately relapse. Residual treatment-surviving is considered responsible for outgrowth of AML. In many retrospective studies, detection minimal residual disease (MRD) has been shown to enable identification these poor-outcome by showing its independent prognostic impact. Most studies focus on molecular markers or analyze data in retrospect. This study establishes value immunophenotypically assessed MRD...
A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers 47 countries to the 2014 survey. Trends include: continued growth transplant activity, more so Eastern European than west; a increase use haploidentical family donors (by 25%) and slower for unrelated donor HSCT. The cord blood as source has decreased again 2014. Main indications HSCT leukemias: 11 853 (33%; 96%...
Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic engineered to express CAR targeting membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment refractory/relapsed acute lymphoblastic leukemia children and young adults as well relapsed/refractory diffuse large B-cell lymphoma, while axicabtagene ciloleucel (Yescarta™) high-grade lymphoma primary mediastinal lymphoma. Both agents genetically CD19....
Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55′668 deaths in 114′491 patients HSCT (83.7% allogeneic) for leukemia were investigated landmark analysis causes of death at day 30 (very early), 100 (early), 1 year (intermediate) 5 years (late). Mortality from all decreased cohort (1980–2001) 2 (2002–2015) post-transplant phases autologous HSCT. After allogeneic HSCT,...
Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade lymphoma mantle cell lymphoma. Products other diseases such as multiple myeloma follicular are likely to be by the European Medicines Agency near future.The Society Blood Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT EBMT (JACIE) Haematology Association...
Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number transplants done in Europe associated countries continues to rise with 45,418 HCT 41,100 patients [(17,155 allogeneic (42%) 23,945 autologous (58%)] reported by 683 centers 50 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid 26,488 (64%; 19% solid tumors 1,607 (3.9%; 2% nonmalignant 2,667 (7%; 81% allogeneic). Trends donor...
Extending the success of cellular immunotherapies against blood cancers to realm solid tumors will require improved in vitro models that reveal therapeutic modes action at molecular level. Here we describe a system, called BEHAV3D, developed study dynamic interactions immune cells and patient cancer organoids by means imaging transcriptomics. We apply BEHAV3D live-track >150,000 engineered T cultured with patient-derived, solid-tumor organoids, identifying 'super engager' behavioral cluster...
Abstract Graft-versus-host disease (GVHD) is the most important complication of allogeneic hematopoietic stem cell transplantation (alloHSCT). We performed a prospective randomized, multicenter, phase 3 trial to study whether posttransplant cyclophosphamide (PT-Cy) combined with short course cyclosporine A (CsA) would result in reduction severe GVHD and improvement GVHD-free, relapse-free survival (GRFS) as compared combination CsA mycophenolic acid (MPA) after nonmyeloablative (NMA) matched...